Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock falls 72.2% from a year ago
Common stock stood at $5K at the end of Q1 FY2026, down 72.2% from a year earlier and up 0.0% from the prior quarter.
Context
- Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Common stock increased in 1 of the last 2 fiscal years.
What to watch
Whether common stock keeps falling in the next quarterly balance sheet after a -72.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 5K USD
- Year-over-year change
- -68.8%
- 2-year CAGR
- +11.8%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5K | -68.8% |
| FY2024 | 2024-12-31 | 16K | +300.0% |
| FY2023 | 2023-12-31 | 4K | — |
Common Stock vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's Mar 2026 common stock of $5K is the 3rd highest of the 8 companies compared; the peer median is $2K.
- Its year-over-year change of -72.2% is the 5th highest of 7, against a peer median of -28.3%.
- Common stock amounts to 0.1% of total assets for PLYX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28K | -56.6% | -19.8% | 0.0% | |
| Mar 2026 | $6K | +0.0% | +14.5% | 0.0% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | Mar 2026 | $5K | -72.2% | — | 0.1% |
| Mar 2026 | $5K | +66.7% | +35.7% | 0.0% | |
| Mar 2026 | $2K | -93.3% | -56.9% | 0.0% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $2K | +0.0% | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding PLYX) | $2K | -28.3% | -2.7% | 0.0% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Cash & Equivalents | 2K | 4.62M | 5.14M |
| Short-term Investments | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 27K |
| Total Current Assets | 2.32M | 5M | 5.17M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 250K |
| Other Non-current Assets | 0 | 0 | 0 |
| Total Non-current Assets | 0 | 0 | 250K |
| Total Assets | 2.32M | 5M | 5.42M |
| Account Payables | 473K | 72K | 470K |
| Short-term Debt | 128K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 |
| Other Current Liabilities | 1K | 1K | 114K |
| Total Current Liabilities | 1.04M | 289K | 605K |
| Long-term Debt | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 250K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 250K |
| Total Liabilities | 1.04M | 289K | 855K |
| Common Stock | 4K | 16K | 5K |
| Retained Earnings | (60.29M) | (90.65M) | (99.64M) |
| Accumulated OCI | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Total Equity | 1.28M | 4.71M | 4.57M |
| Total Debt | 128K | 0 | 0 |
| Net Debt | 126K | (4.62M) | (5.14M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.